RT Journal Article SR Electronic T1 Optimizing treatment for community-acquired pneumonia through a care bundle JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA4534 DO 10.1183/13993003.congress-2019.PA4534 VO 54 IS suppl 63 A1 Markus Fally A1 Emma Diernaes A1 Line Molzen A1 Regitze Seerup A1 Simone Israelsen A1 Jacob Anhoj A1 Pernille Ravn YR 2019 UL http://erj.ersjournals.com/content/54/suppl_63/PA4534.abstract AB Introduction: Community-acquired pneumonia (CAP) is a common disease causing high morbidity and mortality. Numerous studies indicate that guideline-based treatment can reduce antibiotic exposure, length of stay, mortality and health care costs in CAP. Although we have a huge number of these practice guidelines, several studies, including a pilot study from one of our centres, indicate that physicians show low grade of adherence to them.Aim: The aim of this study was to assess and improve adherence to CAP guidelines by implementing a CAP care bundle and analyse the outcomes.Methods: The optiCAP study was designed as a quality improvement project at three hospital sites in Denmark. We monitored adherence to guidelines by defining a care bundle consisting of CURB-65 score, lower respiratory tract samples, chest X-ray and antibiotics within 8 hours of arrival. Interventions, such as staff education and optimizing patient flow took place after a baseline period from March to October 2018.Results: In total, 1284 CAP cases were included. We saw a significant increase in the proportion of patients receiving bundle care from 22% in the baseline period to 60% in the last months of the intervention period (p < 0.05). Until now, the achieved improvements are lasting in the follow-up period as well.Conclusion: In the baseline period, only every fifth patient received the recommended care for CAP. During the intervention period, we saw a significant improvement in the proportion of patients receiving bundle care. Whether these improvements are lasting and have an impact on morbidity, mortality and antibiotic exposure will be assessed after the follow-up period that ends in February 2019 and presented at the upcoming ERS congress.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4534.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).